Seattle Genetics News

OVERLAND PARK, Kan.-- --The Board of Directors of Waddell & Reed Financial, Inc.

Seattle Genetics Inc. said it's signed an cancer drug agreement with drug developer Millennium: The Takeda Oncology Co.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Seattle Genetics, Inc. , today announced that its management will host a teleconference at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on Tuesday, December 15, 2009, to discuss brentuximab vedotin partnering.

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 , in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

U.S. stock futures gained Friday after the government reported retail sales climbed 1.3% in November, better than expected.

Welcome to Deal Stocks. Stocks in Friday's news are Bank of New York Mellon Corp.

Intraday data provided by Interactive Data Real Time Services , a division of Interactive Data Corp.

NEWTON, Mass.-- --Hospitality Properties Trust today announced that it will begin paying a quarterly cash distribution to common shareholders of $0.45/share --iShares, a global leader in Exchange Traded Funds, announced today that in celebration of iShares 529 Plan's new sponsorship of the Museum of Discovery, it ha... RIO DE JANEIRO & NEW YORK-- ...

Die Clea... LONDON-- --FUND db x-trackers DJ STOXX@ Telecommunications Short Daily ETF DEALING DATE 04-Dec-09 NAV PER SHARE EUR28.0782 NUMBER OF SHARES IN ISSUE 70... NEW YORK-- --MetLife, Inc.

Dec 1, 2009 - Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and dacetuzumab programs will be reported at the upcoming 51st American Society of Hematology 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana.

LANHAM, Md.-- --Pitney Bowes Business Insight, the leading global provider of data quality and location intelligence solutions, today announced the availability of the Customer Communica... DALLAS-- --The January 2010 issue of SUCCESS, the preeminent publication for personal achievement, recognizes five people who in 2009 made an impact, led by ...

BOTHELL, Wash. & SANTA MONICA, Calif.-- --Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companiesa antibody-drug conjugate collaboration.

Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Wednesday evening.

Our analysts have issued complimentary analysis on the following six companies: Seattle Genetics Inc.

Development-stage biotechnology company Seattle Genetics Inc. said Thursday its third-quarter loss narrowed on higher revenue from partnerships.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/15/09, Seattle Genetics, Inc., announced it will report its third quarter 2009 financial results on Thursday, October 22, 2009, after the close of financial markets.

Bruce J. Seeley has been named executive vice president, commercial at Seattle Genetics .

Seattle Genetics has discontinued the SeaGen MARINER clinical trial of dacetuzumab based on a determination that the trial would be unlikely to meet its primary endpoint.